ArriVent BioPharma, Inc. (AVBP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.69
- As of
Kresmion compiles this page from AVBP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ArriVent BioPharma, Inc. (AVBP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full AVBP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AVBP on one page. Preview it with sample data, then open it live with a free account.
Preview the AVBP dossierActive events for AVBP
- mediumEarnings above estimates
Q3-2026: Beat consensus by 25.1%, EPS $-0.81 vs $-1.0818 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 66% of AVBP (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 82% of AVBP (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +136% to AVBP (2026Q2)
- high13F: funds added
3 tracked funds increased AVBP this 2026Q1 - institutional consensus
FREE, NO ACCOUNT
Every event on AVBP, as it fires
You are seeing 5 of 11 events recorded on AVBP since 2026-05-26.
The five above landed across 3 days. The other 6 were recorded on 1 other days. 6 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, AVBP
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on AVBP
AVBP against its peers
AVBP's return on equity of -54.1% ranks in the 37th percentile of 22 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | AVBP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 10.3M | n/a | 9 |
| Operating margin | n/a | -477.0% | n/a | 8 |
| Net margin | n/a | -445.6% | n/a | 8 |
| Return on equity | -54.1% | -44.8% | 37 | 22 |
| 1 year | -42.3% | 12.4% | 16 | 21 |
Peers (22): FDMT, OLMA, ANNX, DBVT, ACHV, NVCT, KURA, IMMX, HELP, BCAX, XOMA.D, DSGN, SGMT, WVE, JANX, ABUS, CGEM, CLYM, AURA, GERN, SLDB, PRME. Left out: APMD (no annual filing), ATTO (no annual filing), ANL (period gap). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (AVBP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in AVBP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on AVBP in the last 180 days.
Upstream: SEC EDGAR filings for AVBP
Kresmion, "ArriVent BioPharma, Inc. (AVBP) institutional holdings and SEC filings", data as of 2026-11-14, https://kresmion.com/research/AVBP. Upstream data: SEC EDGAR filings for AVBP.
Link to this data (HTML):
<a href="https://kresmion.com/research/AVBP">ArriVent BioPharma, Inc. (AVBP) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow AVBP on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to AVBP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.